The frequency of macrophage activation syndrome and disease course in systemic juvenile idiopathic arthritis

References

• Petty RE, Laxer RM, Wedderburn LR. Juvenile idiopathic arthritis. In: Petty RE, Laxer RM, Lindsey CB, Wedderburn LR, editors. Textbook of Pediatric Rheumatology. 7th ed. Philadelphia: Elsevier; 2016. p. 188–204.
   Google Scholar
• Petty RE, Southwood TR, Manners P, Baum J, Glass DN, Goldenberg J, et al. International League of Associations for Rheumatology classification of juvenile idiopathic arthritis: second revision, Edmonton, 2001. J Rheumatol 2004;31(2):390–2.
   PubMed Web of Science ®Google Scholar
• Çakan M, Aktay-Ayaz N, Keskindemirci G, Ekinci DY, Karadağ ŞG. Subtype frequencies, demographic features, and remission rates in juvenile idiopathic arthritis – 265 cases from a Turkish center. Turkjpediatr. 2017;59(5):548–54.
   Web of Science ®Google Scholar
• Lee JJY, Schneider R. Systemic Juvenile idiopathic arthritis. Pediatr Clin N Am. 2018;65(4):691–709.
   PubMed Web of Science ®Google Scholar
• Benedetti FD, Schneider R. Systemic juvenile idiopathic arthritis. In: Petty RE, Laxer RM, Lindsey CB, Wedderburn LR, editors. Textbook of Pediatric Rheumatology. 7th ed. Philadelphia: Elsevier; 2016. p. 205–16.
   Google Scholar
• Behrens EM, Beukelman T, Paessler M, Cron RQ. Occult macrophage activation syndrome in patients with systemic juvenile idiopathic arthritis. J Rheumatol 2007;34(5):1133–8.
   PubMed Web of Science ®Google Scholar
• Cron RQ, Davi S, Minoia F, Ravelli A. Clinical features and correct diagnosis of macrophage activation syndrome. Expert Rev Clin Immunol. 2015;11(9):1043–53.
   PubMed Web of Science ®Google Scholar
• Ravelli A, Grom AA, Behrens EM, Cron RQ. Macrophage activation syndrome as part of systemic juvenile idiopathic arthritis: diagnosis, genetics, pathophysiology and treatment. Genes Immun. 2012;13(4):289–98.
   PubMed Web of Science ®Google Scholar
• Ravelli A, Minoia F, Davi S, Horne A, Bovis F, Pistoria A, et al. 2016 classification criteria for macrophage activation syndrome complicating systemic juvenile idiopathic arthritis: a European league against rheumatism/American College of Rheumatology/Paediatric Rheumatology International Trials Organisation Collaborative Initiative. Arthritis Rheumatol. 2016;68:566–76.
   PubMed Web of Science ®Google Scholar
• Wallace CA, Huang B, Bandeira M, Ravelli A, Giannini EH. Patterns of clinical remission in select categories of juvenile idiopathic arthritis. Arthritis Rheum. 2005;52(11):3554–62.
   PubMedGoogle Scholar
• Martini A, Ravelli A, Avcin T, Beresford MW, Burgos-Vargas R, Cuttica R, et al. Toward new classification criteria for juvenile idiopathic arthritis: first steps, pediatric rheumatology international trial organization international consensus. J Rheumatol. 2019;46(2):190–7.
   PubMed Web of Science ®Google Scholar
• Hinze CH, Holzinger D, Lainka E, Haas JP, Speth F, Kallinich T, et al. Practice and consensus-based strategies in diagnosing and managing systemic juvenile idiopathic arthritis in Germany. Pediatric Rheumatol Online J 2018;16(1):7.
   PubMedGoogle Scholar
• Behrens EM, Beukelman T, Gallo L, Spangler J, Rosenkranz M, Arkachaisri T, et al. Evaluation of the presentation of systemic onset juvenile rheumatoid arthritis: data from the Pennsylvania Systemic Onset Juvenile Arthritis Registry (PASOJAR). J Rheumatol 2008;35(2):343–8.
   PubMed Web of Science ®Google Scholar
• Ozen S. Changing concepts in familial Mediterranean fever: is it possible to have an autosomal-recessive disease with only one mutation? Arthritis Rheum 2009;60(6):15757.
   Google Scholar
• Ozen S, Bakkaloglu A, Yilmaz E, Duzova A, Balci B, Topaloglu R, et al. Mutations in the gene for familial Mediterranean fever: Do they predispose to inflammation? J Rheumatol 2003;30(9):2014–8.
   PubMed Web of Science ®Google Scholar
• Ayaz NA, Ozen S, Bilginer Y, Erguven M, Taskiran E, Yilmaz E, et al. MEFV mutations in systemic onset juvenile idiopathic arthritis. Rheumatology (Oxford). 2008;48(1):23–5.
   PubMed Web of Science ®Google Scholar
• Shinar Y, Kosach E, Langevitz P, Zandman-Goddard G, Pauzner R, Rabinovich E, et al. Familial Mediterranean FeVer gene (MEFV) mutations as a modifier of systemic lupus erythematosus. Lupus 2012;21(9):993–8.
   PubMed Web of Science ®Google Scholar
• Minoia F, Davì S, Horne A, Demirkaya E, Bovis F, Li C, et al. Clinical features, treatment, and outcome of macrophage activation syndrome complicating systemic juvenile idiopathic arthritis: a multinational, multicenter study of 362 patients. Arthritis Rheumatol. 2014;66:3160–9.
   PubMed Web of Science ®Google Scholar
• Ravelli A, Minoia F, Davì S, Horne A, Bovis F, Pistorio A, et al. Expert consensus on dynamics of laboratory tests for diagnosis of macrophage activation syndrome complicating systemic juvenile idiopathic arthritis. RMD Open. 2016;2(1):e000161.
   PubMed Web of Science ®Google Scholar
• Singh-Grewal D, Schneider R, Bayer N, Feldman BM. Predictors of disease course and remission in systemic juvenile idiopathic arthritis: significance of early clinical and laboratory features. Arthritis Rheum. 2006;54(5):1595–601.
   PubMedGoogle Scholar
• Lomater C, Gerloni V, Gattinara M, Mazzotti J, Cimaz R, Fantini F. Systemic onset juvenile idiopathic arthritis: a retrospective study of 80 consecutive patients followed for 10 years. J Rheumatol 2000;27(2):491–6.
   PubMed Web of Science ®Google Scholar
• Dewoolkar M, Cimaz R, Chickermane PR, Khubchandani RP. Course, outcome and complications in children with systemic onset juvenile idiopathic arthritis. Indian J Pediatr. 2017;84(4):294–8.
   PubMed Web of Science ®Google Scholar
• Miyamae T, Yokoya S, Yamanaka H, Yokota S. Effect of tocilizumab on growth impairment in systemic juvenile idiopathic arthritis with long-term corticosteroid therapy. Mod Rheumatol. 2014;24(4):567–71.
   PubMed Web of Science ®Google Scholar
• Stoll ML, Cron RQ. Treatment of juvenile idiopathic arthritis: a revolution in care. Pediatr Rheumatol. 2014;12(1):13.
   PubMedGoogle Scholar
• Ravelli A, Martini A. Remission in juvenile idiopathic arthritis. Clin Exp Rheumatol 2006;24(6 Suppl 43):S105–10.
   PubMed Web of Science ®Google Scholar
• Vastert SJ, de Jager W, Noordman BJ, Holzinger D, Kuis W, Prakken BJ, et al. Effectiveness of first-line treatment with recombinant interleukin-1 receptor antagonist in steroid-naïve patients with new-onset systemic juvenile idiopathic arthritis: results of a prospective cohort study. Arthritis Rheumatol. 2014;66(4):1034–43.
   PubMed Web of Science ®Google Scholar